235 related articles for article (PubMed ID: 36073208)
21. Elevated Expression of NOP16 as a Novel Prognostic Biomarker of Prostate Cancer.
Yang T; Sun F; Zhang C; Wang Z; Yang K; Xu Y; Liu Q
Ann Clin Lab Sci; 2023 Jul; 53(4):587-597. PubMed ID: 37625836
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications and oncogenic roles of MYBL2 protein expression in esophageal squamous-cell carcinoma.
Qin H; Li Y; Zhang H; Wang F; He H; Bai X; Li S
Onco Targets Ther; 2019; 12():1917-1927. PubMed ID: 30881043
[TBL] [Abstract][Full Text] [Related]
23. SALL4 correlates with proliferation, metastasis, and poor prognosis in prostate cancer by affecting MAPK pathway.
Zhou J; Peng S; Fan H; Li J; Li Z; Wang G; Zeng L; Guo Z; Lai Y; Huang H
Cancer Med; 2023 Jun; 12(12):13471-13485. PubMed ID: 37119046
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of
Sun SS; Fu Y; Lin JY
Oncol Lett; 2020 Apr; 19(4):2765-2772. PubMed ID: 32218829
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.
Xin Z; Li Y; Meng L; Dong L; Ren J; Men J
Math Biosci Eng; 2022 Jan; 19(2):1825-1842. PubMed ID: 35135230
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH.
Xiong YC; Wang J; Cheng Y; Zhang XY; Ye XQ
Mol Cell Biochem; 2020 May; 468(1-2):185-193. PubMed ID: 32200471
[TBL] [Abstract][Full Text] [Related]
27. [miR-129 in the diagnosis, treatment and prediction of clinical prognosis of prostate cancer].
Zhao XD; Tang ZL; Wang ZH; Dong J; Xu S
Zhonghua Nan Ke Xue; 2022 Nov; 28(11):996-1005. PubMed ID: 37846115
[TBL] [Abstract][Full Text] [Related]
28. MYBL2 in synergy with CDC20 promotes the proliferation and inhibits apoptosis of gastric cancer cells.
Deng Q; Wu L; Li Y; Zou L
Adv Clin Exp Med; 2021 Sep; 30(9):957-966. PubMed ID: 34358419
[TBL] [Abstract][Full Text] [Related]
29. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
31. Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer.
Guo Z; Chen X; Du T; Zhu D; Lai Y; Dong W; Wu W; Lin C; Liu L; Huang H
Med Oncol; 2017 Jan; 34(1):13. PubMed ID: 28012134
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNA LINP1 promotes the malignant progression of prostate cancer by regulating p53.
Wu HF; Ren LG; Xiao JQ; Zhang Y; Mao XW; Zhou LF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4467-4476. PubMed ID: 30058678
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
[TBL] [Abstract][Full Text] [Related]
34. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
35. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
36. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
37. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
38. Knockdown MTDH Inhibits Glioma Proliferation and Migration and Promotes Apoptosis by Downregulating MYBL2.
Fu J; Peng J; Tu G
Mediators Inflamm; 2022; 2022():1706787. PubMed ID: 36133745
[TBL] [Abstract][Full Text] [Related]
39. PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
Li E; Liu L; Li F; Luo L; Zhao S; Wang J; Kang R; Luo J; Zhao Z
Prostate; 2017 Dec; 77(16):1563-1572. PubMed ID: 28971496
[TBL] [Abstract][Full Text] [Related]
40. Circ_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143.
Li M; Liu Y; Liu J; Li W; Li N; Xue D; Zhang X; Wang P
Aging (Albany NY); 2019 Nov; 11(22):10626-10643. PubMed ID: 31756170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
